Leukemia, Myeloid, Acute: all 3,035 studies

Page 12 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.

• Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesCompletedNCT01823198Phase 1/2Results posted
• Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HMCompletedNCT01816230Phase 1/2Results posted
• Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or OlderCompletedNCT01814826Phase 1Results posted
• GRASPA Treatment for Patients With Acute Myeloblastic LeukemiaCompletedNCT01810705Phase 2Results posted
• Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic SyndromeCompletedNCT01807091Not applicableResults posted
• Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01806571Phase 2Results posted
• Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01804101Not applicableResults posted
• Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT01802333Phase 3Results posted
• Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
• Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)CompletedNCT01786343Phase 2Results posted
• Unrelated Umbilical Cord Blood (UBC)TransplantationCompletedNCT01768845Not applicableResults posted
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic MalignanciesCompletedNCT01760655Phase 2Results posted
• Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete RemissionCompletedNCT01757535Phase 3Results posted
• Azacitidine in Patients Undergoing Matched Unrelated Stem Cell TransplantationTerminatedNCT01747499Phase 1/2Results posted
• Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic MalignanciesTerminatedNCT01745913Phase 2Results posted
• Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid LeukemiaCompletedNCT01743859Phase 2Results posted
• Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous LeukemiaTerminatedNCT01743807Phase 1Results posted
• Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous LeukemiaCompletedNCT01736943Phase 2Results posted
• Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT01729845Phase 1/2Results posted
• Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)CompletedNCT01721876Phase 3Results posted
• Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01707004Phase 2Results posted
• Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDSCompletedNCT01700673Phase 2Results posted
• Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia TreatmentCompletedNCT01698879Phase 2Results posted
• A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous PlerixaforCompletedNCT01696461Phase 2Results posted
• Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid LeukemiaCompletedNCT01696084Phase 3Results posted
• BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to RelapseCompletedNCT01690624Phase 1Results posted
• Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic SyndromesCompletedNCT01690520Phase 2Results posted
• Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01687400Phase 2Results posted
• Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)CompletedNCT01687387Phase 2Results posted
• Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01664897Phase 2Results posted
• Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)CompletedNCT01662505Phase 1Results posted
• Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T CellCompletedNCT01660607Phase 1/2Results posted
• A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating MutationsCompletedNCT01657682Phase 2Results posted
• Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete RemissionTerminatedNCT01656252Phase 1/2Results posted
• A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic LeukemiaCompletedNCT01656031Phase 2Results posted
• Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell TransplantTerminatedNCT01640301Phase 1/2Results posted
• T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic TransplantTerminatedNCT01621477Phase 2Results posted
• Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
• Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TARCompletedNCT01611298Not applicableResults posted
• Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDSTerminatedNCT01607645Phase 2Results posted
• Double Cord Versus Haploidentical (BMT CTN 1101)CompletedNCT01597778Phase 3Results posted
• Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell BehaviorTerminatedNCT01588951Phase 2/3Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01565668Phase 2Results posted
• Rasburicase and Allopurinol in Treating Patients With Hematologic MalignanciesTerminatedNCT01564277Phase 2Results posted
• Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)CompletedNCT01550224Phase 2Results posted
• A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01546038Phase 2Results posted
• Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive GenotypeCompletedNCT01534260Phase 1/2Results posted
• A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched RelativesTerminatedNCT01532635Phase 2Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01527045Phase 2Results posted
• Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating MutationsCompletedNCT01522469Phase 2Results posted
• CNDO-109-AANK for AML in First Complete Remission (CR1)Status unknownNCT01520558Phase 1/2Results posted
• Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic MalignanciesCompletedNCT01499147Not applicableResults posted
• Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell TransplantationCompletedNCT01491958Phase 2Results posted
• A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic LeukemiaTerminatedNCT01486784Phase 1/2Results posted
• Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)CompletedNCT01475370Phase 1Results posted
• Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
• Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT01471444Phase 3Results posted
• Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in RemissionTerminatedNCT01465386Phase 2Results posted
• T-Cell Depleted Double UCB for Refractory AMLTerminatedNCT01464359Phase 2Results posted
• Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous MalignanciesCompletedNCT01461538Phase 2Results posted
• Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 RegimenCompletedNCT01457885Phase 2Results posted
• Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)TerminatedNCT01451437Phase 1Results posted
• Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDSTerminatedNCT01442714Phase 2Results posted
• A Phase I Study of OCV-501 in Acute Myeloid Leukemia PatientsCompletedNCT01440920Phase 1Results posted
• A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT01440374Phase 2Results posted
• Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
• Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT01420926Phase 2Results posted
• AC220 for Children With Relapsed/Refractory ALL or AMLCompletedNCT01411267Phase 1Results posted
• Reduced Intensity Double Umbilical Cord Blood TransplantationCompletedNCT01408563Phase 2Results posted
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesCompletedNCT01384513Phase 2Results posted
• Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT01378416Phase 1Results posted
• Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01371981Phase 3Results posted
• Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell TransplantationCompletedNCT01371656Phase 3Results posted
• Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body IrradiationTerminatedNCT01366612Phase 3Results posted
• Tipifarnib in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT01361464Phase 2Results posted
• A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid LeukemiaCompletedNCT01358734Phase 2Results posted
• Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative DonorCompletedNCT01350245Phase 2Results posted
• Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01349972Phase 2Results posted
• Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT01349049Phase 1/2Results posted
• Phase I Study of OPB-51602 in Patients With Hematologic MalignanciesCompletedNCT01344876Phase 1Results posted
• Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT01342887Phase 1/2Results posted
• Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)TerminatedNCT01339910Phase 3Results posted
• Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow TransplantationCompletedNCT01338987Phase 2Results posted
• Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction ChemotherapyCompletedNCT01334086Phase 2Results posted
• Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT01326728Results posted
• Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid LeukemiaCompletedNCT01307579Phase 3Results posted
• Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell TransplantCompletedNCT01305200Phase 3Results posted
• A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01303796Phase 3Results posted
• Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDSCompletedNCT01300572Phase 1Results posted
• Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)CompletedNCT01295710Phase 3Results posted
• Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous LeukemiaTerminatedNCT01289678Phase 2Results posted
• Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic SyndromeCompletedNCT01289457Phase 1/2Results posted
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
• Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT01272245Phase 2Results posted
• WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)CompletedNCT01266083Phase 2Results posted
• SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)CompletedNCT01261312Phase 1/2Results posted
• AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01253447Phase 2Results posted
• Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT01253070Phase 2Results posted

← Leukemia, Myeloid, Acute overview